EU HTA Joint Clinical Assessment (JCA): FAQ

The EU HTA Regulation (EU) 2021/2282 introduces Joint Clinical Assessments (JCAs) as a new EU-level clinical assessment process for certain categories of medicinal products. As the framework is being implemented in phases, JCAs are becoming an increasingly relevant part of the path from development and regulatory review to later national HTA use in EU Member States.

For health technology developers (HTD), the JCA is not just a parallel procedural requirement running alongside the EMA centralised procedure. It also has direct implications for evidence planning, dossier strategy, and the later national HTA and access pathway. That is why JCA readiness begins well before submission and, where relevant, should be considered early together with a JSC.

The following sections provide a practical overview of what is mandatory, what falls within scope, how the JCA procedure works in practice, what HTD need to submit and when, and how Member States are expected to use the JCA report. It also highlights practical considerations for regulatory HTA, and market access teams preparing for the EU HTA procedures.

 

What is a Joint Clinical Assessment (JCA)?

A Joint Clinical Assessment is an EU-level scientific assessment of clinical evidence on the relative effects on health outcomes. For medicinal products, it is intended to produce a common clinical assessment at EU level that can then be used by Member States in their subsequent national HTA work. The JCA focuses on comparative clinical assessment of a product, while pricing, reimbursement, and broader value conclusions remain at Member State level.

Key takeaway: A JCA creates one common EU-level clinical assessment, but it does not replace national HTA, pricing, or reimbursement decisions.

 

What is the legal basis for JCAs?

JCAs are established under Regulation (EU) 2021/2282 on health technology assessment (HTAR). This Regulation establishes the EU framework for joint clinical assessments, joint scientific consultations and cooperation between Member States in the HTA field. For medicinal products, the Regulation sets out which products fall within scope, how the JCA process is triggered, how assessors and co-assessors are appointed, how the report is prepared and endorsed, and how Member States are expected to use the published JCA output in their national work. The detailed implementation of the framework is further supported by implementing acts, methodology guidance and procedural guidance adopted at EU level.

Key takeaway: JCAs are not a voluntary exercise: they are grounded in a formal EU-level framework with defined scope, process steps, and obligations for Member State use.

 

Which medicinal products are subject to JCA (and when)?

The JCA rollout for medicinal products follows a stepwise approach. From 12 January 2025, JCAs apply to medicinal products with a new active substance (NAS) for the treatment of cancer and to advanced therapy medicinal products (ATMPs).

From January 2028 orphan medicinal products will be in scope and from January 2030 all other centrally authorised medicinal products submitted as full applications under Article 8(3) of Directive 2001/83/EC will require a JCA. By contrast, generics, hybrids, biosimilars, well-established use applications, fixed combinations, and informed consent applications are outside that scope.

Key takeaway: Developers that are planning an EU centralised MAA or CMA for a NAS oncology product or an ATMP (and later, orphan and other products) should assume a parallel JCA will be required.

 

Does JCA replace national HTA submissions?

No. The JCA provides one common EU-level clinical assessment, but it does not replace national HTA processes. Member States are expected to take the EU-level clinical assessment into account in their subsequent national HTA work. This means that national procedures continue to exist, but the clinical assessment is no longer intended to be repeated independently in full at national level for products covered by JCA. For developers, the practical implications are that one important part of the evidence package will be assessed jointly at EU level, while national HTA processes will continue to build on that output within their own procedural frameworks.

Key takeaway: JCA does not replace national HTA procedures, but it changes their starting point by providing one common EU-level clinical assessment for Member States to use.

 

How does a JCA start and what is the trigger?

For medicinal products, the process is directly linked to the EMA centralised procedure. The developer states in their EMA Letter of Intent whether their application falls within scope of the JCA and then notifies the Member State Coordination Group Secretariat via email.

The EMA notifies the HTA Secretariat of the receipt of a marketing authorisation application, and the developer must submit specified information to the HTA Secretariat alongside their EMA submission.

The JCA process then moves into formal scoping and appointment of an assessor and co-assessor by the JCA subgroup under the Member State Coordination Group on HTA.

Key takeaway: Developers should build JCA readiness early into EMA submission planning.

 

What is the HTA IT platform and how do developers communicate during JCA?

All product-specific communication for a JCA takes place via the secure HTA IT platform, which is used for document exchange and process communication.

The Commission’s JCA page also notes that developers should contact the HTA Secretariat (using the designated mailbox) to obtain platform access and to manage uploads appropriately.

Key takeaway: Companies should define early who owns platform access, document upload, and controlled communication with the EU HTA bodies.

 

What is PICO and why does it matter so much for the JCA?

The scoping phase defines the assessment scope in terms of PICO: Population, Intervention, Comparator(s), Outcomes. This scope determines which evidence questions must be answered in the JCA dossier, and which comparative analyses may be expected during assessment.

The assessor and co-assessor draft the assessment scope, gather Member State input, and finalise the consolidated PICOs before the dossier request is issued.

The developer then has a limited timeframe to address the PICOs which is why early alignment on comparator, populations, and outcomes is so important.

Key takeaway: PICO matters because it determines which population, comparator, and outcomes are relevant for the JCA, and therefore what the evidence package must be able to support.

 

Can developers influence the assessment scope?

The process is designed to reflect Member States’ needs, but the final scope is not negotiated in the way scientific advice would be.

However, developers can request an explanation meeting once the scope is shared and can improve their position substantially through early preparation.

Key takeaway: Robust early thinking on likely comparators, outcomes, and populations reduces the risk that the final PICOs prove difficult to address.

 

What must be submitted in a JCA dossier?

The JCA dossier is expected to contain complete and up-to-date information, data, analyses and evidence addressing the defined scope (PICO). This means not only the underlying study documentation, but also the analyses and evidence synthesis need to answer the assessment questions, including indirect comparisons where relevant. The dossier should therefore be sufficiently structured, traceable, and transparent to allow assessors to understand how conclusions are derived and how the submitted analyses link back to the source material. During the assessment, the assessor/co-assessor can request additional information, and developers may also provide new relevant information on their own initiative.

Key takeaway: Dossier readiness requires not only data availability, but also evidence synthesis, traceability, and auditability.

 

What are the key timelines (and why do they feel tight)?

The critical point is not only the formal deadline for submission of the dossier itself (within 100 days of the Commission’s initial request, or 60 days in accelerated procedures and certain variations) but the compressed sequence of scoping, dossier request, dossier preparation, assessment, factual accuracy review, endorsement, and publication.

Endorsement of the final JCA report should occur no later than 30 days after the Commission grants marketing authorisation.

Key takeaway: JCA readiness cannot begin when the dossier request arrives; much of the evidence package, supporting analyses, and internal review workflow need to be anticipated and structurally prepared well ahead of marketing authorisation submission with rapid dossier assembly capabilities once PICOs are finalised.

 

How does JSC and JCA interact with EMA regulatory assessment?

The EMA centralised procedure and JCA run in parallel, with scoping and dossier submission timed against EMA procedural steps. This parallelism makes it risky to assume that an evidence package optimised for regulatory benefit-risk alone will automatically be sufficient for comparative clinical assessment in HTA.

Where feasible, early structured interactions, including Joint Scientific Consultations – in parallel with EMA scientific advice or as HTA only JSC –enable developers to obtain feedback from regulators and HTA bodies on evidence-generation plans, provided the pivotal trials are still in the planning phase.

Key takeaway: Early consultations can reduce the risk that comparators, endpoints or population choices diverge too far between regulatory and HTA expectations.

 

Who is involved in producing and reviewing the JCA report?

JCAs are conducted by the JCA subgroup of the HTA Coordination Group, which appoints an assessor and co-assessor from different Member States. Their draft report is then reviewed through the formal JCA process, including opportunities for the developer to comment on factual accuracy and to provide clarifications or additional information. The process also involves patients, clinicians, and other relevant expert input reflecting the broader perspective needed for clinical assessment.

Key takeaway: Because JCA involves multiple actors and perspectives, developers should engage early with assessors’ evidence expectations as well as likely patient, clinician and expert viewpoints.

 

What happens at the end of the process?

At the end of the JCA process, the final JCA report is endorsed by the HTA Coordination Group within the defined timeframe and then published after the Commission’s procedural check. Once published, it becomes the common EU-level clinical assessment output that Member States are expected to use in their subsequent national HTA work. For developers, this means that the end of the JCA is not the end of the overall access pathway, but rather the point at which the EU clinical assessment becomes available for downstream national processes.

Key takeaway: JCA ends with a published EU-level report, but its practical importance begins afterwards in national HTA processes.

 

How must Member States use the JCA report?

National authorities are expected to give due consideration to published JCA reports in national HTA work and to reflect that consideration in national HTA documentation.

Member States must also provide information back to the Coordination Group on outcomes, including how the JCA was considered, which informs annual reporting on JCA uptake.

Developers should expect national HTA bodies to reference JCA findings explicitly and to ask country-specific follow-up questions based on that shares EU clinical assessment. A clear bridging narrative between EU-level assessment to country-specific requirements will therefore be important.

Key takeaway: Even with a published JCA report, national HTA bodies are likely to ask country-specific follow-up questions and require explanations that link the common EU assessment to national decision-making.

 

Can a JCA be discontinued?

Yes. Under certain circumstances, the process may be discontinued before the final JCA report is endorsed and published. This can happen, for example, if the underlying regulatory procedure does not continue in a way that supports completion of the JCA, or if the product no longer remains in the process for which the joint assessment was initiated. Another example is if the marketing authorisation application is withdrawn. For developers, this means that a JCA is a formal and structured process, but still one that depends on the continued basis and relevance of the underlying approval pathway.

Key takeaway: A JCA may end without final published report if the underlying regulatory procedure stops, so initiation should not be equated with guaranteed publication.

 

Practical readiness checklist for JCA preparation

Evidence & dossier readiness

• Build an HTA-ready evidence repository well before the marketing authorisation process starts (even before pivotal study design is fixed), including key trial outputs, subpopulation analyses, and indirect comparison inputs.
• Map likely PICO-related pressure points early, especially where comparator, endpoint, or population choices may differ across Member States.
• Prepare for rapid responses to consolidated PICOs (once scope is issued).

 

Process & governance

• Nominate accountable owners for HTA IT platform access, submissions, and controlled communications.
• Pre-plan the internal workflow for the factual accuracy and confidentiality review step on draft reports within short turnaround windows.

 

Early engagement options

• Identify early whether the product is in mandatory JCA scope, when that scope applies, and which exclusions may be relevant.
• Assess whether JSC pathways (parallel EMA–HTA scientific or HTA-only advice) are feasible before the pivotal study begins.
• Consider how the expected JCA findings may later need to be translated into country-specific benefit assessments and pricing and reimbursement decisions.

 

Conclusion

The EU JCA framework is now a core element of the evidence and access pathway for in-scope products, sitting at the interface of regulatory planning, HTA requirements, and downstream market access decision-making. While JCAs do not replace national HTA submissions or national reimbursement decision-making, Member States are expected to give due consideration to JCA outputs in their national HTA. This makes it essential that developers plan evidence-generation strategies, comparative analyses, and dossier readiness in a connected way across regulatory, HTA, and access planning.

For companies, this means that JCA readiness is not simply a matter of meeting a procedural requirement at the time of submission. It depends on whether the evidence package is developed early enough, whether likely PICO-related challenges have been anticipated, and whether internal teams are prepared to respond to the process with the necessary speed, structure, and scientific robustness.

DLRC supports health technology developers with integrated regulatory and HTA readiness, including JSC/JCA-scoping, early simulation of likely PICOs, evidence-gap identification, dossier strategy and assembly, and cross-functional planning to align clinical, regulatory, and market access considerations in the new EU HTA environment. View the full scope of our HTA & Market Access services here.